PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.

• J. Burger,
• M. Sivina,
• E. Kim,
• G. Issa,
• W. Wierda,
• N. Jain,
• P. Thompson,
• A. Ferrajoli

Affiliations

J. Burger

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

M. Sivina

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

E. Kim

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

G. Issa

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

W. Wierda

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

N. Jain

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

P. Thompson

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

A. Ferrajoli

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America